Intended for healthcare professionals


Abemaciclib: Pharma company lawsuit forces Dutch health agency to reassess cancer drug

BMJ 2024; 386 doi: (Published 09 July 2024) Cite this as: BMJ 2024;386:q1520
  1. Elisabeth Mahase
  1. The BMJ

The Dutch healthcare procurement agency has said it will reassess the breast cancer drug abemaciclib after being ordered to do so by the court of Amsterdam, in a case brought by pharmaceutical company Eli Lilly.

The Dutch National Health Care Institute (Zorginstituut Nederland) decides which new drugs should be funded through the healthcare system, in a similar way to the National Institute for Health and Care Excellence (NICE) for the NHS in England and Wales.

The lawsuit was filed in response to the institute’s recommendation to the Dutch health minister not to reimburse the cost of Eli Lilly’s drug abemaciclib (Verzenio) for adults with a certain type of early stage breast cancer, as it …

View Full Text

Log in

Log in through your institution


* For online subscription